Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.
WuXi Biologics (Cayman) Inc. has announced a board meeting scheduled for August 19, 2025, in Hong Kong to consider and approve the interim results for the first half of 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s market positioning.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$23.40 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. operates in the biopharmaceutical industry, providing end-to-end solutions for biologics discovery, development, and manufacturing. The company focuses on offering comprehensive services to global pharmaceutical and biotechnology companies.
Average Trading Volume: 43,277,027
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.9B
See more data about 2269 stock on TipRanks’ Stock Analysis page.